1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
Key Takeaways
- Li-Fraumeni syndrome (TP53) is autosomal dominant with a broad early-onset core tumor spectrum—soft-tissue and osteosarcoma, premenopausal breast cancer, brain tumors, adrenocortical carcinoma, and leukemias—requiring cautious radiation and whole-body surveillance concepts
- Von Hippel–Lindau (VHL) features hemangioblastomas, clear-cell renal cell carcinoma, pheochromocytoma, and endolymphatic sac tumors with genotype-informed pheochromocytoma risk counseling
- MEN1 (MEN1) centers on parathyroid, pituitary, and enteropancreatic neuroendocrine tumors; MEN2 (RET) centers on medullary thyroid carcinoma with gene-specific prophylactic thyroidectomy timing and pheochromocytoma/hyperparathyroidism patterns by MEN2A/2B
- NF1 (NF1) is common, AD, with café-au-lait macules, neurofibromas, and tumor risks including MPNST and optic pathway glioma; NF2-related schwannomatosis (NF2) is dominated by bilateral vestibular schwannomas
- Diagnostic strategy matches hallmark tumors to syndrome genes, confirms germline variants, then applies syndrome-specific surveillance—avoid one-size-fits-all “hereditary cancer” scripts
1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
Quick Answer: Match hallmark tumors to genes: TP53 (LFS core cancers), VHL (hemangioblastoma/RCC/pheo), MEN1 (3 Ps), RET (MTC ± pheo/HPTH; MEN2B phenotype), NF1 (CALMs/neurofibromas/MPNST), NF2 (bilateral vestibular schwannomas). All major entities here are autosomal dominant with syndrome-specific surveillance.
After HBOC and Lynch/polyposis, Domain 1C expects fluent recognition of rarer but high-stakes cancer predisposition syndromes. Exam vignettes often give one pathognomonic tumor (adrenocortical carcinoma in a child; bilateral vestibular schwannomas; medullary thyroid cancer) and ask for the gene, inheritance, or next management concept.
Li-Fraumeni Syndrome (LFS) — TP53
| Element | Board-level content |
|---|---|
| Inheritance | Autosomal dominant; TP53 tumor suppressor |
| Core tumors (“classic”) | Soft-tissue sarcoma, osteosarcoma, premenopausal breast cancer, brain tumors, adrenocortical carcinoma (ACC), leukemias |
| Natural history | Very early onset possible; multiple primary cancers common across the lifespan |
| Diagnostic clues | Childhood ACC or choroid plexus carcinoma strongly prompts TP53 evaluation; soft-tissue/osteosarcoma + family pattern |
Management Themes
- Breast surveillance for women often resembles high-risk protocols (MRI; discussion of risk-reducing mastectomy in shared decision-making).
- Whole-body MRI and structured protocols (e.g., “Toronto protocol”–style comprehensive surveillance) appear in LFS care concepts—know that surveillance is multimodal and starts early.
- Radiation sensitivity / second-malignancy concern: avoid unnecessary radiation when alternatives exist; therapeutic radiation decisions are oncology-led but counselors flag the issue.
- Cascade testing has profound psychosocial implications because of childhood risks and reproductive decisions.
Chompret criteria and classic LFS criteria are clinical selection tools—similar in spirit to Amsterdam for Lynch: helpful, incomplete alone.
Von Hippel–Lindau Disease — VHL
VHL is autosomal dominant. Hallmark lesions:
| Tumor / feature | Notes |
|---|---|
| CNS / retinal hemangioblastomas | Cerebellum, brainstem, spine, retina—vision and neurologic morbidity |
| Clear-cell renal cell carcinoma | Often multifocal/bilateral; nephron-sparing strategies |
| Pheochromocytoma / paraganglioma | Genotype correlates with risk (certain missense variants higher pheo risk) |
| Pancreatic cysts / NETs | Surveillance component |
| Endolymphatic sac tumors | Hearing loss clue |
| Epididymal / broad ligament cystadenomas | Benign but syndromic clues |
Counseling centers on lifelong coordinated surveillance (ophthalmology, CNS imaging, abdominal imaging, biochemical pheo screening) rather than a single prophylactic surgery. Distinguish VHL from other hereditary pheo/PGL syndromes (SDHx, RET, NF1, MAX, TMEM127) when the vignette is pheo-first.
Multiple Endocrine Neoplasia
MEN1 — MEN1
| “3 P” core | Detail |
|---|---|
| Parathyroid | Primary hyperparathyroidism—often multigland; earliest/most penetrant feature |
| Pituitary | Prolactinoma and other adenomas |
| Enteropancreatic neuroendocrine tumors | Gastrinoma (Zollinger-Ellison), insulinoma, others—malignant potential |
Additional features can include foregut carcinoids, adrenocortical lesions, and facial angiofibromas/collagenomas. Inheritance is AD. Management is biochemical and imaging surveillance plus targeted surgery—not one universal risk-reducing operation like MEN2 thyroidectomy.
MEN2 — RET
| Subtype | Hallmarks | Counseling anchor |
|---|---|---|
| MEN2A | Medullary thyroid carcinoma (MTC), pheo, hyperparathyroidism | RET codon correlates with MTC aggressiveness and prophylactic thyroidectomy timing |
| MEN2B (MEN3) | Very early/aggressive MTC, pheo, mucosal neuromas, marfanoid habitus, ganglioneuromatosis | Highest-risk RET variants (e.g., p.Met918Thr classically)—thyroidectomy discussed in infancy in specialty care |
| FMTC | MTC-predominant familial pattern | Still RET-related spectrum |
Prophylactic thyroidectomy timed by RET genotype is a defining MEN2 management concept and a frequent exam target. Always screen for pheochromocytoma before thyroid surgery when indicated—anesthesiology/surgical safety point genetic counselors should mention in preoperative counseling coordination.
Neurofibromatosis Type 1 and NF2-Related Schwannomatosis
| Feature | NF1 (NF1) | NF2 (NF2, Merlin) |
|---|---|---|
| Inheritance | AD; ~50% de novo | AD; frequent de novo |
| Cutaneous | Café-au-lait macules, skinfold freckling, cutaneous neurofibromas | Less “classic CALM” story; skin schwannomas possible |
| Hallmark tumors | Optic pathway glioma, plexiform neurofibromas, malignant peripheral nerve sheath tumor (MPNST) | Bilateral vestibular schwannomas; other schwannomas, meningiomas, ependymomas |
| Other | Learning differences, skeletal dysplasia, hypertension/pheo (less common than VHL/MEN2) | Hearing loss, balance problems dominate quality of life |
| Cancer counseling | MPNST risk education; breast cancer risk modestly increased in women—surveillance awareness | Tumor burden management; hearing preservation strategies |
Clinical diagnostic criteria (NIH/revised) still matter because many NF1 diagnoses are clinical; molecular confirmation helps atypical cases and cascade testing. Schwannomatosis (SMARCB1/LZTR1) is a related differential when vestibular schwannomas are absent.
Other High-Yield Predisposition Pointers (Brief)
| Syndrome | Gene(s) | One-line hallmark |
|---|---|---|
| Gorlin (nevoid BCC) | PTCH1, SUFU | Multiple basal cell carcinomas, jaw keratocysts, medulloblastoma risk (SUFU) |
| Cowden / PTEN hamartoma | PTEN | Macrocephaly, hamartomas, breast/thyroid/endometrial risks |
| Hereditary retinoblastoma | RB1 | Childhood retinoblastoma ± later sarcoma risk; radiation caution |
| Familial atypical mole–melanoma | CDKN2A | Melanoma ± pancreatic cancer risk discussions |
| Hereditary pheo/PGL | SDHB/C/D, etc. | SDHB higher malignancy concern |
Use these when a vignette sits outside HBOC/Lynch/LFS/VHL/MEN/NF—but master the primary five first.
Cross-Cutting Diagnostic and Counseling Strategy
- Hallmark tumor → syndrome shortlist (ACC child → LFS; MTC → RET; hemangioblastoma + RCC → VHL; bilateral vestibular schwannomas → NF2).
- Offer germline testing with pretest counseling about childhood-onset implications when relevant (TP53, RET MEN2B, RB1).
- Assign syndrome-specific surveillance (not generic “annual mammogram only”).
- Address risk-reducing surgery where established (notably genotype-guided thyroidectomy in MEN2; selective discussions in LFS breast risk).
- Implement cascade testing and coordinate multidisciplinary care (endo, neurosurgery, ophthalmology, oncology).
| Syndrome | Inheritance | Signature teaching tumor(s) | Signature management concept |
|---|---|---|---|
| LFS | AD (TP53) | Sarcoma, ACC, early breast, brain, leukemia | Comprehensive surveillance; radiation caution |
| VHL | AD (VHL) | Hemangioblastoma, ccRCC, pheo | Lifelong multi-organ surveillance |
| MEN1 | AD (MEN1) | Parathyroid, pituitary, pancreatic NET | Biochemical/imaging surveillance |
| MEN2 | AD (RET) | MTC ± pheo ± HPTH | Genotype-timed prophylactic thyroidectomy |
| NF1 | AD (NF1) | OPG, plexiforms, MPNST | Tumor vigilance; clinical + molecular diagnosis |
| NF2 | AD (NF2) | Bilateral vestibular schwannomas | Hearing-preserving tumor management |
These syndromes repay pattern recognition: one hallmark feature correctly identified often unlocks the entire counseling plan.
A 3-year-old is diagnosed with adrenocortical carcinoma. Which hereditary syndrome should be highest on the genetic counseling differential?
Which tumor triad best matches von Hippel–Lindau disease for exam recognition?
A young adult with medullary thyroid carcinoma and a pathogenic RET variant is counseled about family members. Which management concept is most specific to MEN2?
Which comparison between NF1 and NF2 is most accurate?